Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update (Businesswire) - May 13, 2025 - "Kezar is responding to the information request from the FDA Division of Hepatology and Nutrition to resolve the partial clinical hold on the PORTOLA Phase 2a clinical trial."
FDA event • Autoimmune Hepatitis
|